Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BNT162b2

- PMLiVE

Russia becomes first country to approve a COVID-19 vaccine

Vaccine approved after less than two months of human testing

- PMLiVE

US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine

Latest deal is part of Operation Warp Speed

- PMLiVE

Novavax plans to meet US COVID-19 vaccine demand in 2021

Company plans to produce two billion doses if vaccine proves effective

- PMLiVE

AI: the smart money is on the smart thinking

Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

Socially distanced strategising

The new normal can improve how you create strategy

- PMLiVE

J&J inks $1bn deal with US for coronavirus vaccine

Agreement includes manufacturing and delivery of 100 million doses

- PMLiVE

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

ALK inhibitor improved progression-free survival in first-line setting

- PMLiVE

Novavax reports promising phase 1 results for coronavirus vaccine

Candidate induced immune response in early-stage clinical trial

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Eli Lilly begins COVID-19 prevention trial in nursing homes

Trial will investigate monoclonal antibody in up to 2,400 participants

White paper: The impact of COVID-19 on chronic disease management

Therapy Watch, Research Partnership's syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, Research Partnership share some of the insights and...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links